Experimental autoimmune myasthenia gravis in naive non-obese diabetic (NOD/LtJ) mice: Susceptability associated with natural IgG antilbodies to the acetylcholine receptor

International Immunology

Volumn 15, Issue 1, 2003, Pages 11-16

  Quintana, Francisco J ^a   Pitashny, Milena ^a   Cohen, Irun R ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Autoantibodies; Autoimmunity; Homunculus

Indexed keywords

CHOLINERGIC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC OBESITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; MYASTHENIA GRAVIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RECEPTORS, CHOLINERGIC;

EID: 0037253847     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxg003     Document Type: Review

References (51)

1. Quintana, F. J. and Cohen, I. R. 2001. Autoantibody patterns in diabetes-prone NOD mice and in standard C57BL/6 mice. J. Autoimmun. 17:191.
2. Christadoss, P., Poussin, M. and Deng, C. 2000. Animal models of myasthenia gravis. Clin. Immunol. 94:75.
3. Lindstrom, J. M., Seybold, M. E., Lennon, V. A., Whittingham, S. and Duane, D. D. 1998. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975. Neurology 51:933.
4. Al-Lozi, M. and Pestronk, A. 1999. Organ-specific autoantibodies with muscle weakness. Curr. Opin. Rheumatol. 11:483.
5. Paas-Rozner, M., Dayan, M., Paas, Y., Changeux, J. P., Wirguin, I., Sela, M. and Mozes, E. 2000. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc. Natl Acad. Sci. USA 97:2168.
6. Quintana, F. J., Rotem, A., Carmi, P. and Cohen, I. R. 2000. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J. Immunol. 165:6148.
7. Sitaraman, S., Metzger, D. W., Belloto, R. J., Infante, A. J. and Wall, K. A. 2000. Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice. J. Neuroimmunol. 107:73.
8. Bach, J. F. and Mathis, D. 1997. The NOD mouse. Res. Immunol. 148:285.
9. Sadelain, M. W., Qin, H. Y., Lauzon, J. and Singh, B. 1990. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39:583.
10. Qin, H. Y., Sadelain, M. W., Hitchon, C., Lauzon, J. and Singh, B. 1993. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J. Immunol. 150:2072.
11. Ulaeto, D., Lacy, P. E., Kipnis, D. M., Kanagawa, O. and Unanue, E. R. 1992. A T-cell dormant state in the autoimmune process of nonobese diabetic mice treated with complete Freund's adjuvant. Proc. Natl Acad. Sci. USA 89:3927.
12. Lennon, V. A., Seybold, M. E., Lindstrom, J. M., Cochrane, C. and Ulevitch, R. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147:973.
13. Asher, O., Neumann, D., Witzemann, V. and Fuchs, S. 1990. Acetylcholine receptor gene expression in experimental autoimmune myasthenia gravis. FEBS Lett. 267:231.
14. Kao, I. and Drachman, D. B. 1977. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 196:527.
15. Elson, C. J. and Barker, R. N. 2000. Helper T cells in antibody-mediated, organ-specific autoimmunity. Curr. Opin. Immunol. 12:664.
16. Balasa, B., Deng, C., Lee, J., Bradley, L. M., Dalton, D. K., Christadoss, P. and Sarvetnick, N. 1997. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186:385.
17. Coutinho, A., Kazatchkine, M. D. and Avrameas, S. 1995. Natural autoantibodies. Curr. Opin. Immunol. 7:812.
18. Purkerson, J. and Isakson, P. 1992. A two-signal model for regulation of immunoglobulin isotype switching. FASEB J. 6:3245.
19. Shi, F. D., Zhang, G. X., Bai, X. F., Van der Meide, P. H. and Link, H. 1997. Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats. Clin. Exp. Immunol. 108:523.
20. Fuchs, S., Nevo, D., Tarrab-Hazdai, R. and Yaar, I. 1976. Strain differences in the autoimmune response of mice to acetylcholine receptors. Nature 263:329.
21. Berman, P. W. and Patrick, J. 1980. Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis. J. Exp. Med. 152:507.
22. Berman, P. W. and Patrick, J. 1980. Experimental myasthenia gravis. A murine system. J. Exp. Med. 151:204.
23. + T cells in Graves' disease patients and healthy controls. J. Autoimmun. 8:685.
24. Martin, R., Jaraquemada, D., Flerlage, M., Richert, J., Whitaker, J., Long, E. O., McFarlin, D. E. and McFarland, H. F. 1990. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145:540.
25. Filion, M. C., Bradley, A. J., Devine, D. V., Decary, F. and Chartrand, P. 1995. Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur. J. Immunol. 25:3123.
26. Filion, M. C., Proulx, C., Bradley, A. J., Devine, D. V., Sekaly, R. P., Decary, F. and Chartrand, P. 1996. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Blood 88:2144.
27. Lacroix-Desmazes, S., Kaveri, S. V., Mouthon, L., Ayouba, A., Malanchere, E., Coutinho, A. and Kazatchkine, M. D. 1998. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J. Immunol. Methods 216:117.
28. Holmberg, D., Freitas, A. A., Portnoi, D., Jacquemart, F., Avrameas, S. and Coutinho, A. 1986. Antibody repertoires of normal BALB/c mice: B lymphocyte populations defined by state of activation. Immunol. Rev. 93:147.
29. Stahl, D., Lacroix-Desmazes, S., Mouthon, L., Kaveri, S. V. and Kazatchkine, M. D. 2000. Analysis of human self-reactive antibody repertoires by quantitative immunoblotting. J. Immunol. Methods 240:1.
30. Lundkvist, I., Coutinho, A., Varela, F. and Holmberg, D. 1989. Evidence for a functional idiotypic network among natural antibodies in normal mice. Proc. Natl Acad. Sci. USA 86:5074.
31. Hayakawa, K., Asano, M., Shinton, S. A., Gui, M., Allman, D., Stewart, C. L., Silver, J. and Hardy, R. R. 1999. Positive selection of natural autoreactive B cells. Science 285:113.
32. Avrameas, S. 1991. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today 12:154.
33. Grabar, P. 1975. Hypothesis. Auto-antibodies and immunological theories: an analytical review. Clin. Immunol. Immunopathol. 4:453.
34. Ochsenbein, A. F. and Zinkernagel, R. M. 2000. Natural antibodies and complement link innate and acquired immunity. Immunol. Today 21:624.
35. Ochsenbein, A. F., Fehr, T., Lutz, C., Suter, M., Brombacher, F., Hengartner, H. and Zinkernagel, R. M. 1999. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286:2156.
36. Cohen, I. R. and Cooke, A. 1986. Natural autoantibodies might prevent autoimmune disease. Immunol. Today 7:363.
37. Andersson, A., Forsgren, S., Soderstrom, A. and Holmberg, D. 1991. Monoclonal, natural antibodies prevent development of diabetes in the non-obese diabetic (NOD) mouse. J. Autoimmun. 4:733.
38. Cohen, I. R. and Schwartz, M. 1999. Autoimmune maintenance and neuroprotection of the central nervous system. J. Neuroimmunol. 100: 111.
39. Mouthon, L., Haury, M., Lacroix-Desmazes, S., Barreau, C., Coutinho, A. and Kazatchkine, M. D.1995. Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. J. Immunol. 154:5769.
40. h1 autoimmunity. Scand. J. Immunol. 54:21.
41. Maloy, K. J. and Powrie, F. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2:816.
42. + regulatory T cells. Curr. Opin. Immunol. 13:644.
43. Sakaguchi, S., Fukuma, K., Kuribayashi, K. and Masuda, T. 1985. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J. Exp. Med. 161:72.
44. Leslie, D., Lipsky, P. and Notkins, A. L. 2001. Autoantibodies as predictors of disease. J. Clin. Invest. 108:1417.
45. Cohen, I, R. 2000. Tending Adam's Garden: Evolving the Cognitive Immune Self. Academic Press, London.
46. Cohen, I. R. 1992. The cognitive paradigm and the immunological homunculus. Immunol. Today 13:490.
47. Burnet, F. M. 1959. The Clonal Selection Theory of Acquired Immunity Cambridge University Press, Cambridge.
48. Slavin, A., Ewing, C., Liu, J., Ichikawa, M., Slavin, J. and Bernard, C. C. 1998. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 28:109.
49. Krause, I., Tomer, Y., Elias, D., Blank, M., Gilburd, B., Cohen, I. R. and Shoenfeld, Y. 1999. Inhibition of diabetes in NOD mice by idiotypic induction of SLE. J. Autoimmun. 13:49.
50. Raz, I., Elias, D., Avron, A., Tamir, M., Metzger, M. and Cohen, I. R. 2001. [Beta]-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358:1749.
51. Steinman, L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational-therapy. Neuron 24:511.